| Literature DB >> 24657947 |
Stelios Florinas1, Jaesung Kim1, Kihoon Nam1, Margit M Janát-Amsbury2, Sung Wan Kim3.
Abstract
The major drawback hampering siRNA therapies from being more widely accepted in clinical practice is its insufficient accumulation at the target site mainly due to poor cellular uptake and rapid degradation in serum. Therefore, we designed a novel polymeric siRNA carrier system, which would withstand serum-containing environments and tested its performance in vitro as well as in vivo. Delivering siRNA with a system combining an arginine-grafted bioreducible polymer (ABP), microbubbles (MBs), and ultrasound technology (US) we were able to synergize the advantages each delivery system owns individually, and created our innovative siRNA-ABP-MB (SAM) complexes. SAM complexes show significantly higher siRNA uptake and VEGF protein knockdown in vitro with serum-containing media when compared to naked siRNA, and 25k-branched-polyethylenimine (bPEI) representing the current standard in nonviral gene therapy. SAM complexes activated by US are also able to improve siRNA uptake in tumor tissue resulting in decelerating tumor growth in vivo.Entities:
Keywords: Cancer; Microbubbles; RNAi; Ultrasound; VEGF; siRNA
Mesh：
Substances：
Year: 2014 PMID： 24657947 PMCID： PMC4025968 DOI： 10.1016/j.jconrel.2014.03.025
Source DB: PubMed Journal: J Control Release ISSN： 0168-3659 Impact factor: 9.776